Stakeholders applauded FDA's announcement that it would hold a two-day public hearing to gather input on off-label medical product issues, but they are already pulling the agency in several different directions in terms of a desired policy approach.
FDA is finally jumping into the minefield of off-label prescribing with its Nov. 9-10 meeting, following years of push from...





